600196 On Other Exchanges
Symbol
Exchange
600196 is not on other exchanges.

shanghai fosun pharmaceuti-a (600196) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FOSUN PHARMACEUTI-A (600196)

Related News

No related news articles were found.

shanghai fosun pharmaceuti-a (600196) Related Businessweek News

No Related Businessweek News Found

shanghai fosun pharmaceuti-a (600196) Details

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a healthcare company, engages in the research, development, manufacture, trade, and sale of pharmaceutical products in Mainland China and internationally. It offers metabolism and alimentary system drugs for the treatment of chronic hepatitis B, diabetes, chronic atrophic gastritis and gastralgia, flatulence, anorexia, eructation, and pyrosis; and anti-infection drugs to treat malaria, cefmetazole sodium sensitive bacterial infections, tuberculosis, sensitive gram-positive bacterial infections, and viral pneumonia and upper respiratory tract infections. The company also provides cardiovascular and blood system drugs for antithrombotic treatment, ductus dependent congenital heart diseases, hypoxaemia relief, and chronic hepatitis; and the treatment of myocarditis, sinus syndrome, coronary heart disease, cardiomyopathy, arrhythmia, hypertension, microangiopathy, varicose veins syndrome, microcirculatory disorders, hypercholesterolemia, anemia, and chronic renal failure, as well for various dialysis treatments. In addition, it offers oncology drugs for the treatment of lung, breast, prostate, gastric, colorectal, and nasopharyngeal cancers, as well as for malignant pleural mesothelioma; and vaccines for the prevention of influenza. Further, the company provides central nervous system drugs; and crude drugs and intermediates. Additionally, it develops, manufactures, imports, exports, and sells medical equipment and diagnostic products; provides healthcare, hospital management, and consulting services; and researches and develops chemical drugs. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

17,842 Employees
Last Reported Date: 03/29/16
Founded in 1994

shanghai fosun pharmaceuti-a (600196) Top Compensated Officers

Co-Chairman
Total Annual Compensation: CNY7.2M
Compensation as of Fiscal Year 2015.
shanghai fosun pharmaceuti-a
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Board Meeting, Jan 12, 2017

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Board Meeting, Jan 12, 2017. Agenda: To discuss and approve the proposal of phase III unlocking of restricted A shares involved in Incentive Plan (Amendment) of Restricted Shares.

Kite Pharma and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Establish Joint Venture in China to Develop and Commercialize Autologous T-Cell Therapies to Treat Cancer

Kite Pharma and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced a joint venture, Fosun Pharma Kite Biotechnology Co., Ltd. to develop, manufacture and commercialize axicabtagene ciloleucel in China with the option to include additional products, including two T cell receptor (TCR) product candidates from Kite. Axicabtagene ciloleucel (KTE-C19), Kite’s lead product candidate, is an investigational chimeric antigen receptor (CAR) T-cell therapy under development for the treatment of B-cell lymphomas and leukemias. The joint venture will be registered in Shanghai and owned equally between Kite Pharma, a pioneer in the field of engineered T-cell therapy for cancer, and Fosun Pharma, a leading healthcare group in China. Under the terms of the agreement, Fosun Pharma will provide the RMB equivalent of $20 million in funding to support clinical development and manufacturing activities and Kite will provide certain technical transfer services to the joint venture. Each party will share in any profits from the joint venture with Kite Pharma receiving 40% and Fosun Pharma receiving 60%. Kite will also receive an upfront fee of $40 million from the joint venture, funded by Fosun Pharma, regulatory and commercial milestones totaling $35 million and mid-single digit sales royalties for axicabtagene ciloleucel (KTE-C19). The joint venture will initially focus on axicabtagene ciloleucel, Kite’s lead CAR product candidate for the treatment of B-cell lymphomas and leukemias. The joint venture will also have the option to license additional product candidates including KITE-439, a TCR therapy directed against the human papillomavirus type 16 E7 oncoprotein and KITE-718, a TCR therapy directed against MAGE A3 and MAGE A6, antigens frequently found in solid tumors including bladder, esophageal, head and neck, lung and ovarian cancers. Opt-in and milestone payments for KITE-439 and KITE-718 could total $140 million plus profit sharing and mid-single digit sales royalties. Kite Pharma's product candidate, axicabtagene ciloleucel, is an investigational therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. Axicabtagene ciloleucel has been granted Breakthrough Therapy Designation status for diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) regulatory support for DLBCL in the EU.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Board Meeting, Jan 10, 2017

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Board Meeting, Jan 10, 2017. Agenda: To discuss and approve the proposal of jointly investing in establishing Fosun Pharmaceutical Kite Biotechnology (China) Co., Ltd. with KP EU C.V.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

600196 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600196.
View Industry Companies
 

Industry Analysis

600196

Industry Average

Valuation 600196 Industry Range
Price/Earnings 21.1x
Price/Sales 4.1x
Price/Book 3.0x
Price/Cash Flow 18.3x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SHANGHAI FOSUN PHARMACEUTI-A, please visit www.fosunpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.